Northern Trust Corp Invests $1.63 Million in Pieris Pharmaceuticals, Inc. (PIRS) Stock
Northern Trust Corp acquired a new stake in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 321,118 shares of the biotechnology company’s stock, valued at approximately $1,625,000. Northern Trust Corp owned about 0.75% of Pieris Pharmaceuticals at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. State of Wisconsin Investment Board acquired a new stake in Pieris Pharmaceuticals during the 2nd quarter valued at approximately $132,000. Acadian Asset Management LLC acquired a new stake in Pieris Pharmaceuticals during the 2nd quarter valued at approximately $162,000. Rhumbline Advisers acquired a new stake in Pieris Pharmaceuticals during the 2nd quarter valued at approximately $184,000. Schwab Charles Investment Management Inc. acquired a new stake in Pieris Pharmaceuticals during the 2nd quarter valued at approximately $292,000. Finally, Teachers Advisors LLC acquired a new stake in Pieris Pharmaceuticals during the 2nd quarter valued at approximately $308,000. Institutional investors and hedge funds own 50.45% of the company’s stock.
A number of analysts have weighed in on PIRS shares. HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of Pieris Pharmaceuticals in a research report on Friday, November 10th. ValuEngine downgraded shares of Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $9.00.
Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.05. The company had revenue of $3.93 million during the quarter, compared to the consensus estimate of $1.52 million. Pieris Pharmaceuticals had a negative net margin of 321.83% and a negative return on equity of 221.93%. The company’s revenue for the quarter was up 400.3% on a year-over-year basis. research analysts predict that Pieris Pharmaceuticals, Inc. will post -0.72 earnings per share for the current year.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Stock Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.